FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
Shares of Ventyx Biosciences (NASDAQ: VTYX) are up significantly Monday (up 62.5% at the time of writing), with analysts pointing to the approval of Bristol Myers Squibb's (NYSE: BMY) deucravacitinib on Friday night.
Jefferies analyst Michael Yee reiterated a Buy rating and raised the firm's price target on the stock to $60 from $30 in a note reacting to the news. Yee explained that "VTYX has the potentially cleanest oral TYK2 inhibitor. The first one from BMY has just been approved, importantly with a very clean label... More
Evercore analyst Josh Schimmer comments on Ventyx Biosciences (NASDAQ: VTYX) "We got the much-anticipated deucrava label with no black box warning - rather language noting its unclear if TYK2 will carry JAK risks which makes sense. This has been a top incoming query with... More
Credit Suisse analyst Tiago Fauth reiterated an Outperform rating and $63.00 price target on Ventyx Biosciences Inc (NASDAQ: VTYX).
The analyst comments "Bristols Deucravacitinib Approved in Psoriasis (PsO): Friday, deucravacitinib was approved by the FDA for the treatment of moderate-to-severe psoriasis, making it the first approved... More
Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $50.00 price target on Ventyx Biosciences Inc (NASDAQ: VTYX).
The analyst comments "No black box warning opens the door to broader inflammatory franchise for VTYX - here is why. Given the clean label from FDA, we believe that the read through to VTYX will support a rally the shares tomorrow, and we would expect the positive... More
Stifel analyst Alex Thompson reiterated a Buy rating and $45.00 price target on Ventyx Biosciences Inc (NASDAQ: VTYX).
The analyst comments "The approval of BMY's deucravacitinib (Sotyktu) with no JAK-like black box (label) represents a near best case for the next-gen TYK2 space (VTYX, Nimbus, Alumis, others), as we believe consensus (and our base case) largely anticipated... More
(Updated - September 12, 2022 8:12 AM EDT)
Oppenheimer analyst Jeff Jones raised the price target on Ventyx Biosciences Inc (NASDAQ: VTYX) to $65.00 (from $40.00) while maintaining a Outperform rating.
The analyst comments "Late Friday BMY announced the approval of deucravacitinib-SotyktuTM (Press Release). Key... More
Ventyx Biosciences (NASDAQ: VTYX) Climbs 44%
... More
